Women beware before dying your hair or using hormonal contraceptives, as they may increase your chances of breast cancer. The trial tracked over 60,000 women aged from 55 to 69, for a period of 20 years.
Weight gain is common for those undergoing breast cancer treatment, but putting on pounds can be extremely risky for patients with breast cancer.
The findings showed the use of other hormonal contraceptives was associated with 32 per cent higher breast cancer risk among women under 50 when compared to those who did not use hormonal contraceptives.
Overall survival was 88 per cent for women with no pregnancy, 82 per cent for those with breast cancer while pregnant, and about 97 per cent for women who got pregnant six months or more after a breast cancer diagnosis. Researchers said this study is the first to examine the long-term impact of exercise before a cancer diagnosis and the cardiovascular benefits of exercise across all types of cancer treatments.
"Based on our results, we do not see a detrimental effect of soy food intake among women who were treated with endocrine therapy", Dr Zhang said.
On the other hand, there's been concern that consuming soy-based foods can interfere with the effectiveness of breast cancer drugs such as tamoxifen.
A 2015 study by Toledo and Colleagues indicated that the risk of getting invasive breast cancer was reduced by 68 percent in people who consumed a Mediterranean diet supplemented with EVOO.
"That is a really important message when we're talking about pregnancy and cancer, making sure that you have that option available". Heart disease is the leading cause of death in the United States, and women who have been diagnosed with early-stage breast cancer face a markedly increased risk of heart disease compared to the general population. None of the women who followed a Mediterranean diet suffered a recurrence of the disease.
The researchers from University of Helsinki (Finland) and Cancer Registry of Finland conducted a research in this regard and on hormonal contraceptives.
Physical activity reduces the risk of disease recurrence and comorbidities in survivors of breast cancer.
Oestrogen-receptor negative (ER-negative) breast cancer is an aggressive form of postmenopausal breast cancer.